A5027680603- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Urinary and Genital Oncology Studies
- Bladder and Urothelial Cancer Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Inflammatory Biomarkers in Disease Prognosis
- Biochemical and Molecular Research
- Viral-associated cancers and disorders
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Lung Cancer Treatments and Mutations
- Kruppel-like factors research
- Lung Cancer Research Studies
Hanyang University Guri Hospital
2020-2024
Samsung Medical Center
2018-2022
Sungkyunkwan University
2018-2022
Korea University
2003
Antitumor immune responses induced by checkpoint inhibitors anti-PD-1 or anti-PD-L1 have been used as therapeutic strategies in advanced non-small cell lung cancer (NSCLC) patients over the last decade. Favorable antitumor activity to is correlated with high PD-L1 expression, increased tumor-infiltrating lymphocytes, and decreased suppressive cells including Treg cells, myeloid-derived suppressor tumor-associated macrophages various types. In this study, we investigated potential correlation...
Abstract The major suppressive immune cells in tumor sites are myeloid derived suppressor (MDSCs), tumor‐associated macrophages (TAMs), and Treg cells, the roles of these include hindering T‐cell activities supporting progression survival. In this study, we analyzed pattern circulating MDSC subtypes patients with non‐small cell lung cancer (NSCLC) whether those hinder leading to poor clinical outcomes. First, verified PMN‐MDSCs, monocytic‐MDSCs (M‐MDSCs), increased according stages NSCLC,...
Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy prospectively collected tumour samples from 25 CRC patients receiving cetuximab (an EGFR inhibitor). Of patients, 13 displayed cetuximab; 12 were intrinsically sensitive. obtained six re-biopsy at the sensitive patients. NCOA4–RET LMNA–NTRK1 fusions...
Although anti-programmed death-1 (PD-1) treatment has shown remarkable anti-tumor efficacy, immune-related adverse events (irAEs) develop with heterogeneous clinical manifestations. However, the immunological understanding of irAEs is currently limited. In present study, we analyzed peripheral blood T cells obtained from cancer patients who received anti-PD-1 to determine characteristics irAEs. This study included 31 refractory thymic epithelial tumor (TET) were enrolled in a phase II trial...
Recurrent FGFR2 amplification is observed in gastroesophageal cancers but clinical implications are unknown. We investigated the association of with cytotoxic chemotherapy outcome cancer (GC) patients. Between 2016 and 2018, we identified 1045 metastatic GC patients who received palliative fluoropyrimidine/platinum-based underwent tumor genomic profiling at a tertiary hospital Korea two US centers. retrospectively FGFR2-amplified cases abstracted clinicopathologic features treatment...
Background/Aim: MET exon 14 skipping occurs in 3-4% of patients with lung adenocarcinomas. In this study, we performed a comprehensive analysis clinical data from Korean non-small cell cancer (NSCLC) skipping. Patients and Methods: Overall, 1,020 diagnosed NSCLC between January 2015 July 2017 were analyzed by next-generation sequencing. Results: was identified 20 (1.9%). The median age 69 years (range=39-86 years), 60.0% male, most (55.0%) ever-smokers. For first-line chemotherapy, the...
Objectives: Several factors associated with the prognosis of patients NSCLC have been reported in literature; however, most these cannot be examined preoperatively. In this study, clinical utility platelet parameters who underwent curative resection was evaluated. Materials and Methods: A retrospective study on from July 2006 to September 2016 conducted. The Cox proportional hazard regression model applied evaluate variables that demonstrated effects disease-free overall survival (DFS OS)....
Oropharyngeal squamous cell carcinoma (OPSCC) is the most common neoplasm originating at base of tongue or in tonsils soft palate. In this study, we investigated prognostic value FOXP3+ regulatory T cells OPSCC. Tumor tissues patients with locally advanced OPSCC were analyzed using quantitative multiplex immunohistochemistry. Staining CD8+ cells, conventional CD4+FOXP3- (Tconv cells), CD4+FOXP3+ (Treg CD20+ B and CD68+ macrophages was performed, density evaluated both tumor its stroma. Among...
Purpose: We assessed the clinical feasibility of C-reactive protein to lymphocyte ratio (CLR) as a determinant survival in patients with non-small cell lung cancer (NSCLC) undergoing curative surgical resection. Methods: A retrospective study was conducted on stage I and II NSCLC Demographic variables, including CLR, were collected analyzed. The Cox proportional hazards model used calculate hazard ratios for overall (OS) cancer-specific (CSS). Mann-Whitney U test compare differences between...
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration tumor growth after treatment with anti-PD-1/PD-L1 Abs.However, the immunological characteristics have not been fully elucidated in patients HPD.We prospectively recruited metastatic non-small cell lung cancer treated Abs between April 2015 and 2018, collected peripheral blood before 7-days post-treatment.HPD was defined as ≥2-fold increase both kinetics rate pre-treatment...
Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with IbrutinibThe risk of hepatitis virus (HBV) reactivation during rituximab treatment patients occult HBV infection (hepatitis surface antigen [HBsAg](-) and core antibody [HBcAb](+)) is well known, antiviral prophylaxis strongly recommended.Ibrutinib, selective Bruton tyrosine kinase inhibitor, has been widely used as an effective for chronic lymphocytic leukemia (CLL).It presumed that ibrutinib possible...
Purpose Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, small patient numbers.Materials and Methods Thirteen institutes involved the Consortium for Improving Survival of Lymphoma, a Korean study group, collected clinical data 59 patients treated as salvage therapy between 2016 2022.Results The median age was 60 years (range, 22 to 87 years), 76.3% had advanced...
Immune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin's lymphoma (cHL). We analyzed and safety pembrolizumab or nivolumab patients with pretreated cHL.Clinical data from cancer chemotherapy registry Samsung Medical Center were retrospectively to study cHL treated between Oct 2015 Dec 2018.Of 20 patients, seven (35%) enrolled after a relapse following autologous hematopoietic stem cell transplantation (ASCT) 12 (60%) receipt brentuximab vedotin (BV)....
Purpose To assess the efficacy and safety of docetaxel rechallenge in salvage setting metastatic castration-resistant prostate cancer (mCRPC) patients. Materials methods Clinicopathologic data from patients treated with were collected a single-center registry. Among 227 who received first-line for mCRPC between January 2011 June 2019, 23 undergo after failure to androgen receptor targeting agents and/or cabazitaxel treatment. Endpoints included radiologic progression-free survival (PFS),...
Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated safety atezolizumab mUC patients who failed platinum-based chemotherapy.A retrospective study using Samsung Medical Center cancer chemotherapy registry was performed on 50 consecutive treated atezolizumab, regardless their PD-L1(SP142) status, as salvage therapy...
The CLDN18 gene, encoding claudin 18.1 and 18.2, is a key component of tight junction strands in epithelial cells that form paracellular barrier critical Stomach Adenocarcinoma (STAD).
A widely distributed cell cycle inhibitor, p27, regulates cyclin-dependent kinase-cyclin complexes. Although the prognostic value of p27 has been established for various types carcinomas, its role in luminal breast cancer remains poorly understood. This study aimed to explore functional enrichment and identify potential drug targets patients with luminal-type cancer.